Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
Date:5/3/2010

THE WOODLANDS, Texas, May 3 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its first quarter 2010 financial results on Monday, May 10, 2010 before the financial markets open.  Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 71087289.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through May 17, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present at BIO International Convention
2. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
3. Lexicon Announces Proposed $95 Million Common Stock Offering
4. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
5. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
6. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
7. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
8. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
9. Lexicon Announces Completion of Public Offering of Common Stock
10. Lexicon Announces Pricing of Common Stock in Public Offering
11. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --> ... Market Research titled, "World Synthetic Biology ... the world synthetic biology market to be $5.2 ... segment would continue to lead the market until ... held around half of the market share in ...
(Date:2/5/2016)... ANGELES , Feb. 5, 2016  Redwood Scientific ... a new product designed to help women balance their ... strip delivery technology. Jason Cardiff , ... will be able to help the millions of women ... from the effects of imbalanced hormones. Our research and ...
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Discover the Rocky ... over 1,400 booths and 700 companies. Attendees also get to see the most ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 14th ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... , ... Shark Finds and Kevin Harrington, along with the Product ... with Belly Bands. , Having a dog is great—except when it wets every couch, ... nothing works, get Belly Bands, the easiest way to stop dogs from wetting ...
Breaking Medicine News(10 mins):